Pharsight

Annovera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632066 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10780047 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10765628 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

US11529308 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(15 years from now)

Annovera is owned by Therapeuticsmd Inc.

Annovera contains Ethinyl Estradiol; Segesterone Acetate.

Annovera has a total of 7 drug patents out of which 0 drug patents have expired.

Annovera was authorised for market use on 10 August, 2018.

Annovera is available in ring;vaginal dosage forms.

Annovera can be used as method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles, method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception.

Drug patent challenges can be filed against Annovera from 2022-08-10.

The generics of Annovera are possible to be released after 21 June, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any su...

Dosage: RING;VAGINAL

More Information on Dosage

ANNOVERA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic